UroGen Pharma Ltd.

URGNSEC EDGAR

Pharmaceutical Preparations(L3)CIK: 1668243

Concept	FY2025	FY2024	FY2023	FY2022	FY2021
Revenue from Contract with Customer, Excluding Assessed Tax	$90.4M	$17.2M	$64.4M	$48.0M	$11.8M
Cost of Revenue	$8.9M	$9.4M	$7.7M	$5.2M	$1.0M
Gross Profit	$81.5M	$14.9M	$56.7M	$42.9M	$10.8M
Research and Development Expense	$57.1M	$45.6M	$52.9M	$47.6M	$47.3M
Selling, General and Administrative Expense	$121.2M	$93.3M	$82.8M	$87.5M	$90.2M
Operating Expenses	—	—	—	—	—
Operating Income (Loss)	-$96.8M	-$65.5M	-$79.0M	-$92.3M

Concept	FY2025	FY2024	FY2023	FY2022	FY2021
Assets	$285.7M	$178.3M	$135.6M	$119.7M	$122.0M
Assets, Current	$276.1M	$169.2M	$128.9M	$114.4M	$115.6M
Cash and Cash Equivalents, at Carrying Value	$172.0M	$95.0M	$55.4M	$44.4M	$52.9M
Accounts Receivable, after Allowance for Credit Loss, Current	$20.3M	$15.4M	$12.7M	$11.7M	$7.0M
Inventory, Net	$9.2M	$5.7M	$4.3M	$4.8M	$2.0M
Liabilities	$294.5M	$243.5M	$225.0M	$111.3M	$25.6M
Liabilities, Current	$45.9M	$31.2M	$23.9M	$22.4M

Concept	FY2025	FY2024	FY2023	FY2022	FY2021
Net Cash Provided by (Used in) Operating Activities	-$96.8M	-$76.4M	-$87.6M	-$84.9M	-$105.9M
Net Cash Provided by (Used in) Investing Activities	-$20.6M	-$953.0K	$1.1M	$4.1M	$93.2M
Net Cash Provided by (Used in) Financing Activities	$194.6M	$116.9M	$97.1M	$72.3M	$16.5M
Payments to Acquire Property, Plant, and Equipment	$295.0K	$194.0K	$254.0K	$752.0K	$1.2M

Access SEC EDGAR data via REST API. Free tier available.

from sec_edgar import SecEdgar

api = SecEdgar("YOUR_KEY")
api.revenue("AAPL", limit=5)